We believe investor concerns about cost inflation at Aker BP are overdone, with 87% of its capex covered by the Norwegian state (82% in the year it is incurred) under the temporary regime, versus 78% under the normal tax regime. We estimate that 50% higher capex on its three largest projects in the coming years would only reduce our NAV by ~2.6%. In other news, we made some estimate cuts for Equinor and Vår Energi following trading updates; while we reiterated our BUYs on both, we cut our target...
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
A director at Varian Medical Systems Inc sold/sold after exercising options 6,499 shares at 175.806USD and the significance rating of the trade was 96/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's ...
VARIAN MEDICAL SYST (US), a company active in the Medical Equipment industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date February 23, 2021, the closing ...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
GOOGL currently trades near corporate averages relative to UAFRS-based (Uniform) Earnings, with a 19.5x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to fade from 26% in 2018 to a historical low of 11% by 2023, accompanied by 22% Uniform Asset growth going forward. However, analysts have less bearish expectations, projecting Uniform ROA to only decline slightly to 21% by 2020, accompanied by 22% Uniform Asset growth. Moreover, management is confident about t...
Varian Medical Systems, Inc. (VAR:USA) currently trades above corporate averages relative to UAFRS-based (Uniform) Earnings, with a 26.3x Uniform P/E. At these levels, the market is pricing in bullish expectations for the firm. Additionally, management is confident about their acquisitions, revenue, and growth. Specifically, management is confident they are focusing on four strategic enablers for their patients, and they are confident that the Karolinska University Hospital has begun testing th...
LYB currently trades below corporate averages relative to UAFRS-based (Uniform) Earnings, with a 12.4x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to decline from 19% in 2018 to 8% in 2023, accompanied by 5% Uniform Asset growth going forward. Analysts have similar expectations, projecting Uniform ROA to compress to 15% levels in 2020, accompanied by immaterial Uniform Asset growth. Additionally, management is confident about their M&A strategy, capacity, ...
V currently trades above corporate averages relative to UAFRS-based (Uniform) Earnings, with a 29.1x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to expand from 69% in 2018 to 84% through 2023, accompanied by 11% Uniform Asset growth going forward. Analysts have similar expectations, projecting Uniform ROA to rise to 79% through 2020, accompanied by 9% Uniform Asset growth. However, management may be concerned about their marketing investments, VisaNet, and...
Varian Medical Systems, Inc. (VAR:USA) currently trades near corporate averages relative to UAFRS-based (Uniform) Earnings, with a 21.6x Uniform P/E. At these levels, the market is pricing in bullish expectations for the firm. Additionally, management is confident about their acquisitions, growth, and their long-term outlook. Specifically, management is confident they have booked four initial orders in India under the Tata Trusts framework and that their CTSI acquisition will help the firm be...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Varian Medical Systems' third-quarter results were largely in line with our full-year modeling. The company's upgraded revenue guidance is largely a result of acquisitions closed in the quarter as well as continuing strong software growth. Reinvestments and tariffs, however, have offset the revenue uptick, with earnings remaining in our forecast range. We're maintaining our fair value estimate and wide-moat rating for Varian. The company remains one of the best-positioned device companies in our...
CCL currently trades below recent averages relative to UAFRS-based (Uniform) Earnings, with a 15.5x Uniform P/E. At these levels, the market is pricing in expectations for Uniform ROA to regress from 10% in 2018 to 6% in 2023, accompanied by 2% Uniform Asset growth going forward. Analysts have similar expectations, projecting Uniform ROA to fall to 8% through 2020, accompanied by 7% Uniform Asset growth. That said, management is confident about earnings targets, asset utilization, and their abil...
Varian Medical Systems' second-quarter results were slightly ahead of our forecast on the top line and orders growth. We’re maintaining our fair value estimate for now as the revenue and order outperformance was largely offset by the increase in reinvestments, proton-related expenses, and tariffs. Our wide moat rating is intact. The firm delivered strong results in all of its major geographies. Orders in North America continue to impress; the United States saw 12% growth fueled by several lar...
Varian Medical Systems' second-quarter results were slightly ahead of our forecast on the top line and orders growth. We’re maintaining our fair value estimate for now as the revenue and order outperformance was largely offset by the increase in reinvestments, proton-related expenses, and tariffs. Our wide moat rating is intact. The firm delivered strong results in all of its major geographies. Orders in North America continue to impress; the United States saw 12% growth fueled by several lar...
Varian Medical Systems' second-quarter results were slightly ahead of our forecast on the top line and orders growth. We’re maintaining our fair value estimate for now as the revenue and order outperformance was largely offset by the increase in reinvestments, proton-related expenses, and tariffs. Our wide moat rating is intact. The firm delivered strong results in all of its major geographies. Orders in North America continue to impress; the United States saw 12% growth fueled by several lar...
Key Points: • The decline in interest rates has investors seeking dividend related equities (ex. VZ, POST, VTS, WELL, ESS, O, NNN, EPR, FE, AEP, PNW, and NI) • A few Restaurants acted well despite the plunge in Friday's market (ex. DRI, MCD, YUM, and SBUX) • A few Staples Sector names are attractive. (ex. SJM, POST, SAFM, COKE, and KMB)
Buoyed by growing demand for radiotherapy, or RT, Varian and main competitor Elekta should enjoy sales momentum for the next decade, particularly in the emerging markets. The RT industry has consolidated substantially over the past decade, and the two companies are in prime position to benefit from what we believe is a mid-single-digit growth marketplace.Investors seeking to capitalise on the future of cancer treatments typically focus on drug therapies, which tend to be high-risk/high-reward op...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.